home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Can We Coax the Immune System to Respond Better to Chemotherapy?

  November, 3 2005 21:35
your information resource in human molecular genetics
Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, have discovered a mechanism by which cancer patients’ immune systems respond to chemotherapy. The new finding changes the current understanding of how the immune system responds to chemotherapy and could lead to opportunities for new treatments based on enhancing the body’s immune response to the disease. The study findings appear in Nature Medicine, November 2005.

When a person undergoes chemotherapy, their immune system T-cells are depleted, creating a condition known as lymphopenia. Paradoxically, lymphopenia leads to increased immune system response, but it’s not understood how this happens. Some researchers have believed that chemotherapy only depletes a type of T-cell called a “suppressor” T-cell. This is a type of cell that acts to turn off or inhibit an immune response. Depletion of “suppressor” T-cells increases immune response in cancer patients. However, this new study indicates that even though chemotherapy depletes T-cells, it does not selectively destroy suppressor or regulatory T-cells, as previously assumed. Instead, the study showed that the lymphopenia condition caused by chemotherapy actually provided a good environment for proliferation of suppressor T-cells. Suppressor T-cells actually contribute to the ability of tumors to evade the body’s immune system. The mechanism for this is not entirely clear, but could involve interleukin-2 (IL-2), a cytokine which was not previously associated with suppressing immune responses at all.

Researchers at NCI’s Center for Cancer Research (CCR), Pediatric Oncology Branch, examined immune recovery in 26 young cancer patients with pediatric sarcomas (highly malignant tumors) who received cyclophosphamide-based chemotherapy, which depleted lymphocytes. The patients were then infused with their own frozen lymphocytes, which had been stored before chemotherapy had begun. Researchers examined the impact of this treatment on the patients’ immune recovery with or without recombinant IL-2, an agent that has been considered capable of restoring an immune system weakened by chemotherapy. The cancer patients in the study were assigned to one of three groups: the first group received moderate-dose IL-2 therapy; the second group received low-dose IL-2 treatment, and the third group received no IL-2. The researchers reported that the patients who received IL-2 — at either dose — showed a marked increase in suppressor T-cells after chemotherapy. These findings were confirmed in a parallel study in lymphopenic mice.

“This is a surprising result, since IL-2 has been considered an immune activator — not a suppressor,” commented Crystal L Mackall, M.D., head of CCR’s Pediatric Oncology Branch Immunology Section and study co-author. “These results suggest that a large portion of IL-2’s effects is to suppress immune responses.” If, instead, a way could be designed to deplete the number of suppressor T-cells, that could create a chance for a different type of T-cell — that attacks cancer cells — to increase their numbers to fight the disease, she added.
Such an opportunity may exist, as the researchers also discovered that the suppressor T-cells that appeared following chemotherapy and IL-2 administration were derived from existing T-cells, rather than being created anew in the patients’ thymus glands, where T-cells typically originate. As a result, “if one could deplete suppressor cells from the patient's system, these cells would not be efficiently regenerated,” Mackall explained. “If a patient with lymphocyte depletion were also depleted of suppressor cells, the immune system would be predicted to be highly reactive — and responsive to antitumor vaccines — and therefore may be better able to fight cancer.”
The study has important implications for developing future immunotherapies against cancer, as many researchers are interested in manipulating suppressor cells to make the immune system more effective in responding to cancer. “This study provides the first insight into what makes regulatory T-cells tick and therefore provides ideas for new ways to deplete or manipulate these cells more effectively in humans,” Mackall added.

CCR’s Pediatric Oncology Branch is planning a follow-up clinical trial that will attempt to rebuild the immune system in a similar set of patients who are depleted of suppressor T-cells and also will be administered a tumor vaccine. “We hope that this setting will lead to very vigorous antitumor immune responses that can prevent tumor recurrence,” Mackall said.

Message posted by: Rashmi Nemade

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.